- Retrophin (NASDAQ:RTRX) initiated with Buy rating and $36 (33% upside) price target at Canaccord Genuity citing future catalysts such as proof-of-concept data on CNSA-001 in PKU in early 2019 and Phase 3 data on fosmetpantotenate in PKAN in H2 2019.
- Daré Bioscience (NASDAQ:DARE) initiated with Buy rating at Maxim Group.
- Ligand Pharmaceuticals (NASDAQ:LGND) initiated with Neutral rating and $256 (8% upside) price target at Goldman Sachs.
- Esperion Therapeutics (NASDAQ:ESPR) upgraded to Buy at Citigroup. Shares up 3% premarket.
- Acer Therapeutics (NASDAQ:ACER) upgraded to Strong Buy with a $46 (77% upside) price target at Raymond James. Shares up 10% premarket.
- ATyr Pharma (NASDAQ:LIFE) upgraded to Neutral at Citigroup.
- Amicus Therapeutics (NASDAQ:FOLD) downgraded to Neutral with a $15 (11% upside) price target at Chardan Capital Markets citing diminished prospects for Galafold over the next six months. Shares down 3% premarket.
Premarket analyst action - healthcare
Recommended For You
More Trending News
About TVTX Stock
Related Stocks
Symbol | Last Price | % Chg |
---|---|---|
TVTX | - | - |
Travere Therapeutics, Inc. |